---
anonymous_label: OUT-41
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
output_sha256: c939a2e3ce6573a6645e804ff6329395d1b3a90987c233443d7e037f176145d4
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-41

I recommend that you commit to the **Case Evidence Review**.

### Reasoning and Tradeoffs

You are currently facing a "false positive" signal. Your revenue metrics (expansion bookings, shortened cycles) are contaminated by sales incentives—specifically the bundle pricing and roadmap promises. You cannot trust the financial data to tell you if PlanPilot is providing actual value or if Sales is simply selling a vision.

The usage data is equally ambiguous. A 39% increase in usage is meaningless if the activity is "rerunning samples" (training/demo behavior) rather than solving live production cases. The most alarming signal is the "explainability gap" in the public sector and the analysts falling back to manual notes. This suggests that while PlanPilot can generate a *plausible* draft, it may not be generating a *defensible* one. In B2B workflow software, if a user cannot defend the output to their boss or a regulator, the tool is a liability, not an asset.

**Why not the other options?**
*   **Scale PlanPilot Broadly:** This is the highest-risk move. You have evidence of "silent churn" (the regional administrators) and a lack of analyst stickiness. Scaling now would likely accelerate churn once the bundle pricing expires.
*   **Adoption Quality Sprint:** This measures *behavior*, not *value*. You already know the behavior (analysts use it for two days, then stop). More dashboards won't tell you *why* they stop or if the output is actually wrong.
*   **Demand Cleanroom:** This tests *willingness to pay*, but you don't yet know if the product actually *works* for the end-user. If the product is fundamentally flawed in its logic, a cleanroom only tells you how much you can charge for a flawed product.
*   **Narrow to Public Sector:** This is premature and potentially a mistake, as the public sector currently shows the *worst* adoption due to explainability requirements.

The **Case Evidence Review** is the only option that attacks the "ground truth." By auditing actual files, you move from proxy metrics (clicks and bookings) to outcome metrics (accepted vs. overridden). This tells you if the product is a "productivity booster" or just a "fancy first draft" that requires manual correction.

### The Strongest Reason Against This Recommendation
The Case Evidence Review is slow, qualitative, and "unsexy" to a board that is currently celebrating a strong quarter. It provides no immediate revenue lift and requires manual labor from your most valuable customers. By choosing this, you are effectively telling the CEO: *"The strong quarter might be an illusion created by Sales; we need to stop celebrating and verify the product's utility before we bet next year's budget on it."* This may be perceived as a lack of confidence or "product perfectionism" in the face of commercial momentum.

### Evidence That Would Change My Mind
I would pivot to **Scaling Broadly** if the "silent churn" from the regional administrators was revealed to be unrelated to PlanPilot (e.g., a budget cut or a competitor's move) AND if the "manual notes" behavior was proven to be a preference for hybrid workflows rather than a lack of trust in the tool's accuracy. If you found that 80%+ of PlanPilot suggestions were accepted without modification in the first few audits, the "explainability" issue is a training problem, not a product problem, and you should scale immediately.
